Walvax Biotechnology Co Ltd

300142.SZ · Health Technology · Biotechnology · CN

1,866 employees · walvax.com

About

Walvax Biotechnology Co Ltd is a leading Chinese biotech company specializing in the research, development, production, and marketing of vaccines, antibodies, and diagnostic reagents. The company was founded in 2001 and is headquartered in Beijing. Over the past 20 years, the company has become one of the largest and most advanced biotech companies in the country, capable of offering high-quality and cost-effective products. Walvax Biotechnology is committed to promoting public health and improving people's quality of life. The business model of Walvax Biotechnology is based on the integration of research and development, production, and distribution. The company offers a wide range of products and services and works closely with government agencies and other partners to improve healthcare in China and abroad. The company has various segments, including research and development, vaccine and biological drug production, diagnostic reagent production, and the distribution of medical devices and products. The research and development sector of Walvax Biotechnology has enabled the company to develop a variety of vaccines and biological drugs that contribute to the prevention and treatment of diseases. Some of the company's key vaccines include the Hepatitis A vaccine, Hepatitis E vaccine, rabies vaccine, varicella vaccine, and polio vaccine. In addition, the company has also developed antibody products that can be used for the treatment of cancer and other diseases. Some of the company's key products include the humanized monoclonal antibody against Epidermal Growth Factor Receptor (EGFR) and the humanized monoclonal antibody against Programmed Death-1 (PD-1) receptor. Walvax Biotechnology is also a major producer of diagnostic reagents used for the identification of infections and other diseases. Some of the company's key products include the HIV-ELISA test, HCV-ELISA test, and HBsAg-ELISA test. The distribution sector of Walvax Biotechnology includes the sale of medical devices and products such as blood collection needles and infusion sets. The company has also established partnerships with other companies and organizations to promote the sales and distribution of its products on an international level. Overall, Walvax Biotechnology Co Ltd has become one of China's leading biotech companies. The company has a strong presence in the vaccine industry and has gained a reputation as an innovator and producer of high-quality products. The company is committed to continuing to grow and expand its range of products and services to make a positive contribution to public health.

Annual results

Reported figures, CNY · revenue down 14.6% in 2025

YearRevenueNet incomeNet marginFree cash flow
20252.4B177M7.3%—
20242.8B142M5.0%—
20234.1B419M10.2%—
20225.1B728M14.3%—
20213.5B427M12.3%—

Dividends per share

2026 0.03 CNY2025 0.01 CNY2024 0.01 CNY2023 0.01 CNY2022 0.03 CNY

300142.SZ in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Walvax Biotechnology Co Ltd are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Walvax Biotechnology Co Ltd (300142.SZ) — company profile and financials · MarketPulse